证券研究报告 创新药周报20251130： 口服FXIa抑制剂asundexian预防脑卒中复发III 期成功 本报告由华创证券有限责任公司编制 卖的出价或询价。本报告所载信息均为个人观点，并不构成对所涉及证券的个人投资建议。 请仔细阅读PPT后部分的分析师声明及免责声明。 2025-11-30 证券分析师 刘浩 执业编号：S0360520120002 邮箱：liuhao@hcyjs.com 联系人 段江瑶 邮箱：duanjiangyao@hcyjs.com 联系人 吴昱爽 邮箱：wuyushuang@hcyjs.com @2021 华创版权所有 第一部分 本周创新药重点关注 国内创新药回顾 02 全球新药速递 03 证券研究报告 ┃ 凝血通路：内源性、外源性以及下游共同通路 ┃ 抗凝药物的作用机制对比 资料来源：Omri Cohen, et al.，Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings，Davide Capodanno, et al.，Fac ...

Core Insights - Long-term investment strategies focusing on companies with in-demand products can yield favorable results, particularly in the healthcare sector, though current industry leaders may not always be the best choices [1] Surgical Robotics - Intuitive Surgical expanded its installed base of surgical robots by 13% in Q3 2025, with surgeries performed increasing by 20%, indicating strong demand [3] - Approximately 75% of Intuitive Surgical's revenue comes from parts and services for its robots, presenting a significant growth opportunity, although its P/E ratio is high at 74 [3][5] - Medtronic's P/E ratio is significantly lower at 28, and the company is working to catch up in the surgical robotics market, which could enhance its growth prospects [5][6] Pharmaceutical Sector - Eli Lilly's GLP-1 drugs contributed over 50% of its sales in Q3 2025, leading to a high P/E ratio of 53, but future success is uncertain [7] - Pfizer's P/E ratio of around 15 reflects low investor expectations, partly due to an impending patent cliff and a weak pipeline, despite a high dividend yield of 6.8% [8][10] - Pfizer's acquisition of Metsera, a competitor with a promising drug pipeline, indicates proactive measures to enhance its market position [10] Dividend Stocks - Medtronic has a strong track record with 48 consecutive annual dividend increases, making it an attractive long-term investment option [6] - Johnson & Johnson, known as a Dividend King with over five decades of annual dividend increases, offers a 2.5% dividend yield and operates in both pharmaceutical and medical device sectors [13][14] - J&J's P/E ratio of 20 is moderate compared to other companies, suggesting a more stable investment with less volatility [14] Investment Strategy - While Intuitive Surgical and Eli Lilly are currently popular, their high valuations may not be sustainable long-term, making Medtronic and Pfizer more attractive options for buy-and-hold investors [15][16]

Core Viewpoint - The article emphasizes the potential rewards for investors who remain committed to dividend-paying healthcare stocks, specifically highlighting Bristol Myers Squibb and Johnson & Johnson as strong candidates for income investing. Group 1: Bristol Myers Squibb (BMY) - Bristol Myers Squibb has faced challenges due to patent expirations, particularly for its cancer drug Opdivo and anticoagulant Eliquis, which will lose exclusivity by the end of the decade [3][4] - The company has launched new products, including a subcutaneous version of Opdivo and Reblozyl for anemia, which are expected to drive sales growth [4][6] - In Q3, total revenue increased by 3% year-over-year to $12.2 billion, with the growth portfolio reporting an 18% increase in sales to $6.9 billion [6] - Bristol Myers Squibb has a strong pipeline with numerous products in development, particularly in oncology, including BNT327 in collaboration with BioNTech [7] - The stock offers a forward dividend yield of 5.1%, and the company has increased its payouts by 63.2% over the past decade, making it attractive for income-seeking investors [8] Group 2: Johnson & Johnson (JNJ) - Johnson & Johnson has encountered patent cliffs, legal challenges, and government drug-price negotiations but has still performed well, with Q3 sales rising by 6.8% year-over-year to $24 billion [9] - The company is focused on innovation to navigate challenges, recently launching Imaavy for myasthenia gravis and the AI-powered Virtuguide System for medtech applications [10][12] - Johnson & Johnson boasts a strong balance sheet with the highest credit rating available, indicating its ability to manage obligations and legal issues [13] - The company is recognized as a Dividend King, having raised its payouts for 63 consecutive years, making it a reliable income stock [14][15]

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed, along with the need for diversification. Cramer highlighted that he is fond of the stock, as he said: “You could own JNJ and Merck with their incredible franchises. You know what? I’m actually particularly fond of JNJ right now. They’re spinning off their commoditized artificial joint business.” Photo by Adam Nowakowski on Unsplash Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and m ...

I have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeking Alpha community.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ABBV, ADP, CTAS, FDS, HRL, JNJ, LOW, NEE, O, PEP, TROW, WST either through stock ownership, opti ...

The Dow Jones Industrial Average (^DJI) closed higher on Friday, November 28, 2025, gaining 289.30 (0.61%) points in a shortened Black Friday trading session. Dow Futures (YM=F) also reflected positive sentiment, rising 253.00 (0.5327%). The primary narrative driving the market today was strong optimism surrounding the Black Friday shopping period and the broader holiday retail season, signaling robust consumer spending expectations. This positive outlook propelled a broad range of sectors, particularly tho ...

The Dow Jones Industrial Average (^DJI) was up 289.30 (0.61%) today, with Dow Futures (YM=F) also showing strength, up 253.00 (0.5327%). The positive market momentum in this shortened Black Friday trading session was largely driven by optimism surrounding potential Federal Reserve interest rate cuts in the near future, coupled with generally strong economic data. This sentiment propelled a broad-based rally across the major indices.Several key components and significant stocks posted notable gains. JPMorgan ...

Try our mini crossword with a business twist: Play Fast Company Mini Crossword LOGIN SUBSCRIBE | Custom Studio advertisement In the latest sign that the Trump administration isn't so concerned about asbestos, the Food and Drug Administration this week withdrew a proposed rule that would have required testing for the toxic asbestos in talc-based cosmetics. The rule, which was proposed by the Biden administration less than a year ago, would have required manufacturers to test cosmetics for asbestos and keep r ...

The Dow Jones Industrial Average (^DJI) saw positive movement today, Friday, November 28, 2025, rising 315.72 points or 0.6657% to 47742.84. This upward trend occurred during a shortened Black Friday trading session, with markets closing early at 1 p.m. ET. The broader market narrative was largely driven by renewed optimism for a potential Federal Reserve interest rate cut in December, alongside generally stronger-than-expected economic data. This sentiment helped propel equities despite an overnight techni ...

Women We Admire is pleased to announce The Top 25 Women Editors in Chief for 2025NEW YORK, Nov. 28, 2025 /PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Top 25 Women Editors in Chief for 2025. Editors in chief play one of the most pivotal roles in modern media. As the ultimate decision-makers for what appears on the page or on screen, they guide the editorial vision, shape content strategy, and uphold the standards of accuracy, fairness, and creativity that define trusted journalism. These ...